Simpliciti Spółka z Ograniczoną Odpowiedzialnością (KRS 0001005157, NIP 9462722956) is a Polish company, headquartered in Konin, Wielkopolskie voivodeship. SIMPLICITI operates in: Research and experimental development on social sciences and humanities (PKD 72.20.Z). Industry: Research and development. The company has been listed in the National Court Register since November 29, 2022. SIMPLICITI's most recently reported net revenue was 12.7 K PLN for 2024.
Historical suspension of activities
Suspension: May 31, 2024 - resumed: June 1, 2026
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Simpliciti
Identity
- Name
- Simpliciti Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- November 29, 2022
- Registry status as of
- July 8, 2026
- Latest entry
- July 8, 2026
- Founding act
- 28.11.2022
Articles of association history (3)
- November 28, 2022: 28.11.2022
- 27 GRUDNIA 2022 ROKU, REPERTORIUM A NUMER 21170/2022 NOTARIUSZ PIOTR ŁAŹNIAK, KANCELARIA NOTARIALNA W KONINIE, PRZYJĘTO NOWE BRZMIENIE TEKSTU UMOWY SPÓŁKI.
- 31 PAŹDZIERNIKA 2024 ROKU, REPERTORIUM A NUMER 18725/2024 NOTARIUSZ PIOTR ŁAŹNIAK, KANCELARIA NOTARIALNA W KONINIE, UCHYLONO DOTYCHCZASOWĄ TREŚĆ PAR. 3, KTÓRY OTRZYMAŁ NOWE BRZMIENIE.
Activities
Main activity
72.20.ZResearch and experimental development on social sciences and humanities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. KLECZEWSKA, 10, 52, 62-510, KONIN, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- KONIN
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Simpliciti
Credibility rating
42.5 / 100
Average credibility
Insolvency risk
Low
Elevated threat
Closure risk
48
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/4 yrs
Board changes
0
0/4 yrs
PKD changes
0
0/4 yrs
Name changes
0
0/4 yrs
Data from 4 years of registry activity.
Credibility history
Payment reliability score from 2023–2024
Current: D (43/100)
Trend: improving (+3.6 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2023–2024
Current: 717.29 PLN
Safe: 215.19 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Simpliciti
Founded
November 29, 2022
3 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KONIN
WIELKOPOLSKIE
Primary PKD
72.20.Z
Research and experimental development on social sciences and humani…
Share capital
50.0 K PLN
1,000 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
2 years
2023–2024 · profitable: 0/2
Registry entries
18
latest: July 8, 2026
Risk signals
Revenue
12.7 K PLN
2024
Net profit
-1.7 K PLN
2024
Assets
23.9 K PLN
2024
Equity
20.7 K PLN
2024
EBITDA
470.62 PLN
2024
Valuation
6.9 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Simpliciti.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
